170 results about "Catenin" patented technology

The invention provides a nerve growth factor functionalized exosome as well as a preparation method and application thereof. The functionalized exosome can activate a Wnt / beta-catenin signal channel to maintain dryness of corneal limbal stem cells (LSCs) so as to promote corneal epithelium repair, can activate a cAMP signal channel to relieve inflammatory response and promote corneal nerve regeneration, and can be used for treating or relieving corneal chemical burns, including relieving inflammatory response, reducing stromal scar formation and inhibiting corneal neovascularization. Corneal epithelium repair and nerve regeneration are promoted.

The present invention relates to use of a JWA polypeptide in the preparation of a drug for resisting androgenetic alopecia. An amino acid sequence of the polypeptide is shown as I or II: I: FPGSDRF-Z; II: X-FPGSDRF-Z, wherein an amino acid S is subjected to phosphorylation modification, and X and Z are an amino acid or an amino acid sequence, respectively. The described JWA polypeptide can directly target integrin molecules onto hair follicle cells and enter the cells to play a role in regulating and controlling hair follicle proliferation, promoting hair growth and the like; the telogen phase of the hair follicles is significantly shortened, and the anagen phase of the hair follicles is prolonged; the hair shaft and follicle volume is increased; and the expression level of the target cell integrin molecule αvβ1 can be improved, and the hair follicle stem cell signal channel MEK / ERK / E2F1 / SP1 / Wnt10a / 10b / β-catenin can be accurately activated.

The invention belongs to the technical field of biology, and particularly relates to an anti-hair-loss fish collagen peptide composition with a hair follicle signal channel regulating and controlling function and application of the anti-hair-loss fish collagen peptide composition. The composition can activate a Wnt / beta-catenin signal channel, inhibit a BMP channel, promote hair follicle growth period conversion and hair papilla cell proliferation, repair hair quality and improve the scalp microenvironment at the same time. The composition can be prepared into an oral preparation or an external scalp care product, has the advantages of safety, high efficiency and multi-target regulation, and is suitable for alopecia prevention and hair quality repair.

The invention discloses a traditional Chinese medicine composition for diabetic foot ulcer and a preparation method thereof. Comprising effective extracts of folium ginkgo, radix astragali, rhizoma corydalis and rhizoma anemones raddeanae as active pharmaceutical ingredients. The traditional Chinese medicine composition has an obvious improvement effect on diabetic foot ulcer, the cure rate of a rat with the diabetic foot ulcer can be obviously increased, wound healing is accelerated, and the action mechanism of the traditional Chinese medicine composition is closely related to a Wnt / beta-catenin signal channel. In addition, the traditional Chinese medicine composition provided by the invention also has the advantages of simplicity in preparation, low cost, convenience in carrying and remarkable effect.

Disclosed is an engineered exosome, comprising (a) a KGF polypeptide, fused to a first anchoring polypeptide, (b) a VEGF-Apolypeptide, fused to a second anchoring polypeptide, and (c) a Wnt family member polypeptide involved in Wnt / β-catenin signaling pathway, fused to a third anchoring polypeptide, wherein (a), (b) and (c) are anchored on a membrane of the exosome via the first, second and third anchoring polypeptide, respectively, and wherein the KGF polypeptide, the VEGF-Apolypeptide and the Wnt family member polypeptide are exposed on an outer surface of the membrane of the exosome. Also disclosed are compositions, nucleic acid constructs, and uses of the exosome in treating alopecia and / or canities.

The invention relates to the technical field of biological medicines, in particular to application of OSI-027 in inhibition of proliferation of cells carrying beta-catenin activation mutation. The mTORC inhibitor OSI-027 is found to be capable of inhibiting proliferation of embryo fibroblasts carrying beta-catenin activation mutation and hepatoma carcinoma cells such as HEPA1-6, HUH7, SNU886, HepG2 and HCCLM3, and has no toxic or side effect under a proper dosage; and after the beta-catenin is knocked down, the proliferation inhibition capability of the OSI-027 on HepG2 and HCCLM3 cells is obviously reduced. Therefore, the OSI-027 can be used for preparing a cell proliferation inhibitor carrying beta-catenin activation mutation when the beta-catenin is activated and mutated into a treatment target of the OSI-027.

The present invention provides a method for suppressing a target gene involved in the Wnt / β-catenin signaling pathway in target cells expressing a receptor capable of binding an extracellular Wnt ligand and an intracellular Wnt effector. The method comprises providing nanocarriers and binding the nanocarriers to the target cells and / or internalizing of the nanocarriers into the target cells, whereby the target gene is suppressed in the target cells. In each nanocarrier, an antibody specific for the receptor, a siRNA specific for the effector, or a combination thereof may be attached to a nanoparticle. The target cells may be in a subject. The method may further comprise reducing disease burden and / or inducing stabilization of a disease in the subject. Also provided are methods for synthesizing the nanocarriers.

The invention belongs to the technical field of gene engineering, and particularly relates to a medicine for treating AML (acute myelogenous leukemia) and / or prognosis of AML patients and application of ubiquitin specific protease 20 serving as a target spot in treating acute myelogenous leukemia. The invention provides a medicine for treating AML (acute myelogenous leukemia) and / or prognosis of an AML patient and application of ubiquitin specific protease 20 as a target spot in treating acute myelogenous leukemia, USP20 is used as a super enhancer regulation gene, and the progress of the AML is promoted by combining with CTNNB1, ERG, ELF1 and RUNX1. The knock-down of the USP20 can significantly inhibit AML proliferation in vivo and in vitro. The wnt-beta-catenin pathway can be influenced by interfering the expression of the USP20 so as to influence the progress of AML (acute myeloid leukemia). And the inhibition effect of the inhibitor AS1517499 subjected to virtual screening on the growth of the AML cells is superior to that of a commercial inhibitor GSK2643943A of USP20.

The invention relates to an application of a nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases, the nano antibody is an NB21 nano antibody, and the NB21 nano antibody has an amino acid sequence as shown in SEQ ID No.12. The invention also relates to an application of the nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases. The antibody can specifically block a Wnt / beta-catenin pathway, effectively inhibit expression of proinflammatory factors and relieve inflammatory response of heart tissues, so that occurrence and development of cardiovascular diseases are intervened. The nano antibody has significant advantages in the aspects of intervention accuracy, conversion reliability and the like, and preclinical results show that the nano antibody can improve occurrence and development of ischemic cardiomyopathy; the pharmaceutical composition can be used for treating heart failure, myocarditis and adriamycin cardiomyopathy, can be expanded to systemic inflammatory diseases, realizes the trans-boundary application of one drug with multiple targets, fully verifies the anti-inflammatory effectiveness and safety through in-vivo and in-vitro experimental data, provides new targets, diagnostic tools and accurate intervention schemes for diagnosis and treatment of cardiovascular diseases and systemic inflammatory diseases, and has wide application prospects. The obvious scientific innovation significance and clinical transformation value are realized.

The present invention belongs to the field of biomedicine technology, and relates to small molecule inhibitors and preparation methods and their applications in the preparation of anticancer drugs. Its chemical structural formula is shown in formula (I), and the small molecule inhibitors provided by the present invention have good competitive affinity for the β-catenin / BCL9 target, and can be tightly bound to the target, and have a strong ability to competitively bind to destroy the β-catenin / BCL9 complex. Among them, some small molecule inhibitors have excellent inhibitory effects on the expression of the target gene Axin and better biological activity.

The invention provides application of an RBM39 inhibitor in preparation of beta-catenin mutation liver cancer prevention and treatment products, and belongs to the technical field of beta-catenin mutation liver cancer prevention and treatment drugs. The invention provides an application of RBM39 as a target spot in preparation of a beta-catenin mutation liver cancer prevention and treatment product, and an application of an RBM39 inhibitor in preparation of a beta-catenin mutation liver cancer prevention and treatment product. Tests prove that the RBM39 inhibitor can effectively delay the occurrence and development of the beta-catenin mutant liver cancer in vivo, and the targeted therapy problem of the beta-catenin mutant liver cancer is solved.

The invention discloses an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury, relates to the technical field of biological medicines, and particularly relates to an application of resveratrol in preparation of a medicine for treating pulmonary ischemia reperfusion injury. The resveratrol is used for preparing the medicine for treating the pulmonary ischemia reperfusion injury, and the resveratrol in the medicine inhibits cell apoptosis by activating an RSPO3 / Wnt / beta-catenin signal channel, so that the pulmonary ischemia reperfusion injury is relieved; the resveratrol in the medicine can relieve the pulmonary ischemia reperfusion injury by inhibiting apoptosis of alveolar macrophages induced by hypoxia / reoxygenation; the conditions for inhibiting apoptosis induced by hypoxia / reoxygenation by adopting resveratrol are as follows: the resveratrol with the concentration of 2.5 mu M is adopted to pretreat macrophages; the resveratrol plays a protection role by activating an RSPO3 / Wnt / beta-catenin signal channel, and a new basis is provided for the medical application; the resveratrol is applied to preparation of the medicine for treating the lung ischemia-reperfusion injury, cell apoptosis is inhibited, and lung tissue injury is relieved.

The application discloses a kind of small molecule compound combination and the method for preparing vascular endothelial cell using the small molecule compound combination induced differentiation cell.The method is directed to induce differentiated cell, and finally prepare vascular endothelial cell;The directional induction includes inhibiting the activity of lysine deacetylase, inhibiting the signal path of TGF-β, inhibiting the activity of DNA methyltransferase (DNMT), activating the signal path of WNT / β-catenin and activating the signal path of cAMP.The present application can be converted into vascular endothelial cell by small molecule compound combination induction, and each step can realize accurate quality control, which is convenient for standardized operation and large-scale production.The method provided by the present application has wide donor sources, and the patient himself can be used as a donor, so that the vascular endothelial cells required for basic research, clinical treatment or tissue engineering production can be obtained in a short time.

The present invention relates to a peptide with the activity of promoting hair growth or preventing or inhibiting alopecia. The peptide of the present invention promotes the proliferation of human follicular dermal papilla cells (HFDPC), activates cell proliferation-related signaling proteins and beta-catenin in human dermal papilla cells, enhances the expression levels of beta-catenin downstream genes, down-regulates the expression levels of the hair loss protein DKK-1, increases the expression of keratin proteins in hair outer root sheath cells (HORSC) and up-regulates the expression of transcription factors involved in cell activation in germinal matrix cells (GMC).

The invention belongs to the technical field of bioengineering, and discloses a UBXN10 active polypeptide, a carrier thereof and application of the UBXN10 active polypeptide in anti-cancer drugs. The amino acid sequence of the UBXN10 active polypeptide is as shown in SEQ ID NO: 1, and the nucleotide sequence for coding the UBXN10 active polypeptide is as shown in SEQ ID NO: 2. According to the invention, a plurality of functional means are utilized to analyze the transcriptional activity of cancer promoting beta-catenin in colorectal cancer cells and the antagonism of cancer cell proliferation and stem cell nature. The cell biology level proves that the UBXN10 active polypeptide has the potential of antagonizing beta-catenin mediated proliferation and stem cell gene expression and inhibiting colorectal cancer cell proliferation and stem cell property.

The invention provides an application of 2-indolecarboxylic acid in preparation of a tumor targeted therapy drug. Through computer-aided drug design and molecular docking optimization, 2-indolecarboxylic acid shows high binding energy to an HER2 kinase structural domain. In HER2 positive NCI-N87 gastric cancer cells, the 2-indolecarboxylic acid significantly inhibits cell proliferation and induces G0 / G1 phase arrest and apoptosis. The mechanism research shows that the 2-indoleformic acid can play a role by regulating and controlling the HER2 / Akt / beta-catenin pathway (Western blot verification). In an NCI-N87 cell tumor-bearing nude mouse model, 2-indolecarboxylic acid (15 mg / kg) significantly inhibits tumor growth, and does not cause obvious weight loss or organ toxicity. Immunohistochemical analysis shows that the positive rate of a tumor tissue proliferation marker Ki-67 in a treatment group is remarkably reduced, and apoptosis detection shows that the proportion of TUNEL positive cells is remarkably increased, which indicates that 2-indolecarboxylic acid inhibits tumor cell proliferation and promotes apoptosis at the same time. The invention provides a lead compound with clinical transformation potential for HER2 targeted therapy.

The invention relates to the technical field of biological medicine, in particular to a fibroblast-targeting phycocyanin conjugate, a sol preparation and application of the fibroblast-targeting phycocyanin conjugate, phycocyanin and targeting peptide are covalently linked through an SMCC cross-linking agent, LDL receptor-associated protein 1 highly expressed by fibroblast is specifically recognized through the targeting peptide, and efficient intracellular delivery is achieved; a water-soluble sol preparation carries phycocyanin to break through a cell barrier, and LRP1-rich fibroblasts in a wound are targeted and play a role in the fibroblasts. By inhibiting the EMT process of fiber cells, cell fibrosis and growth of wound bacteria are inhibited, scar formation is reduced, and wound healing is promoted. The defect that natural phycocyanin cells are poor in penetrability is overcome, scar-free healing is achieved by regulating Wnt5a / beta-catenin through targeted delivery, the effect is good, and application and popularization are convenient.

The invention relates to hair-blacking essence and a preparation method thereof. Screening a symbiotic bacterium metabolism extract with small molecule peptide metabolism regulation capability; by combining low-concentration azelaic acid and zinc lactate components, scalp grease oxidation and abnormal proliferation of propionibacterium are inhibited; the expression of IL-10 anti-inflammatory factors is induced, the expression of TNF-alpha and IL-6 is reduced, and the hair follicle microinflammation state is reduced; a Wnt / beta-catenin pathway activator is used for inducing the melanin stem cells to be in a static state; the FGF-2 and the EGF are combined in a micro-dose manner to promote the amplification into precursor cells; mITF regulation peptides and a small amount of trace copper ions are supplemented to induce directional differentiation into mature melanocytes; a microcapsule carrier system with a three-layer structure; the penetration efficiency is improved; antioxidative peptide rich in reduced glutathione, NAD and a promoting factor are used, so that melanocytes are protected from oxidative damage; a coenzyme Q10 type mitochondrial homeostasis regulator is introduced, so that the energy metabolism is improved, the cell aging is delayed, the targeting property is strong, and the effect is accurate.

The present invention provides a cosmetic composition for skin whitening, comprising a specific peptide. The peptide acts as an antagonist for β-catenin, thereby effectively inhibiting β-catenin signaling as well as inhibiting tyrosinase expression and melanin synthesis. As a result, the peptide can be effectively used for skin whitening.

The invention provides a high-transparency and high-simulation bacterial engineering biological cornea as well as a preparation method and application thereof, and belongs to the technical field of tissue engineering cornea materials. According to the method, a bacterial synthetic biology method is adopted, a curvature customization model and an hydroformylation system are combined, and the high-transparency bionic cornea (DBC-L-Cel) which is customized in curvature and shape and has a nanofiber network structure is constructed. The light transmittance of the bionic cornea reaches 91.91%, the light transmittance and the mechanical property of the bionic cornea are matched with those of a natural cornea, and meanwhile the bionic cornea has excellent biocompatibility, adhesiveness and scar resistance. In-vitro experiments show that DBC (at) L-Cel can reduce matrix fibrosis by inhibiting AGE / RAGE / NF [kappa] B and PI3K / AKT pathways and up-regulate Wnt / beta-catenin pathway to activate proliferation, and corneal epithelium is repaired by an adhesion function. In-vivo experiments show that the high-simulation biological cornea DBC-L-Cel is transplanted to a rabbit model with large-scale corneal defects, repair and regeneration of corneal stroma and epithelium can be remarkably promoted, and rapid scar-free repair and reconstruction of the damaged cornea are achieved.

The invention discloses a sterone compound derived from achyranthes bidentata as well as a preparation method and application of the sterone compound. Belongs to the technical field of biological medicine. The invention aims to solve various side effects and defects of the existing medicine for treating glucocorticoid-induced osteoporosis in long-term use. The molecular formula of the compound (SSA) is C33H48O9, the compound (SSA) has a beta-ecdysterone skeleton, and acetal type 5-hydroxymethylfurfural groups are introduced at the positions of side chains C20 and C22. SSA has a remarkable protection effect in a DEX-induced osteoblast injury model, can improve cell viability decline and G1 phase retardation caused by glucocorticoid, and recovers osteogenic differentiation and mineralization ability. The SSA effectively reverses the inhibition effect of DEX on osteoblasts by activating a Wnt / beta-catenin signal channel and up-regulating the expression of RUNX2. SSA has a remarkable anti-osteoporosis function potential.

The present disclosure provides, inter alia, a variety of available agents. In some embodiments, the provided agents can bind to beta-catenin. In some embodiments, the present disclosure provides techniques for modulating beta-catenin function. In some embodiments, the present disclosure provides techniques for the prevention and / or treatment of a condition, disorder or disease associated with beta-catenin. In some embodiments, the present disclosure provides designed amino acids and agents that can provide improved properties and / or activity.

The present invention relates to a multifunctional cascade reactive nano - scale ultrasound contrast agent and its preparation method and application. The contrast agent (GHB - NPs) has a core of chitosan loaded with Basigin - siRNA and modified with hyaluronidase, and a shell membrane of phospholipid - polyethylene glycol - 2GSH. Perfluoropentane is encapsulated inside the shell membrane, and the particle size is 106 - 295 nm. For the GHB - NPs prepared by the present invention, DSPE - PEG2k - 2GSH on its surface can react with highly expressed γ - GGT on the surface of tumor cells, resulting in electrostatic repulsion to expose hyaluronidase, enabling GHB - NPs to penetrate deep into tumor tissues, and having targeting and high efficiency for the treatment of tumors. And it can be used in combination with UTMD. By inhibiting the β - catenin / c - Myc pathway, it down - regulates glycolysis - related proteins and reduces the production of lactic acid and ATP, which is beneficial to the treatment of tumor diseases. And the present invention has experimentally proved that GHB - NPs + UTMD has an obvious therapeutic effect on melanoma model mice, and can be used for the preparation of anti - tumor drugs to achieve the integration of tumor diagnosis and treatment.

The invention provides a polypeptide for enhancing T cell function and application thereof, and belongs to the technical field of biological medicine. The amino acid sequence of the polypeptide disclosed by the invention is as shown in SEQ ID NO. 1. According to the invention, an interaction interface of CLDN18.2 and beta-catenin is targeted for the first time, the full D-type functional polypeptide is designed to realize high-stability and high-affinity protein-protein interaction blocking, and the problem that the interaction site is difficult to target by the traditional antibody drug or small molecule drug is broken through; the used polypeptide PC18.1 has good in-vitro stability and is suitable for subsequent clinical development; the polypeptide is easy to prepare on a large scale through a synthesis means, has the purity of more than or equal to 98%, is low in cost and convenient to modify, and can be flexibly applied to immune combined treatment schemes such as nano-carrier loading and local delivery.

The application provides a kind of nasal mucosa in vitro culture method and culture fluid, the composition of the culture fluid includes Wnt / β-catenin signal pathway activator 0.1-20 μg / ml, fibroblast growth factor 10-150 ng / ml, TGF-β inhibitor 0.02-3 μg / ml, ROCK inhibitor 0.1-100 μmol / L, P38 MAPK inhibitor 0.1-1 μmol / L, serum-free additive 1X, N-acetyl cysteine 1-10 mmol / L, nicotinamide 1-20 mmol / L, GlutaMax additive 1X, antibiotic, DMEM / F12 culture medium 1X.The application can carry out in vitro culture to nasal mucosa, can keep at least 2 weeks of activity, and have complete epithelial barrier and immune system, can realize ex vivo nasal mucosa virus infection experiment.

This invention provides the application of the IFI16 gene as a target in the preparation of bortezomib-resistant drugs for the treatment of multiple myeloma, involving drug targets, related diagnostic reagents, and treatment strategies for the diagnosis and treatment of multiple myeloma (MM). This invention reveals for the first time the core driving role of IFI16 in bortezomib resistance in MM and its novel mechanism of action through the Wnt / β-catenin pathway; more importantly, it provides novel biomarkers, drug targets, and highly feasible combination therapy regimens for accurate prognostic assessment of MM and overcoming the clinically challenging problem of bortezomib resistance, possessing significant theoretical implications and broad clinical application prospects.

Disclosed are inhibitors for the β-catenin / T-cell factor interaction. The inhibitors are selective for β-catenin / T-cell factor over β-catenin / phosphocadherin, and β-catenin / phosphoAPC interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Disclosed herein is a series of helical sulfono-γ-AApeptides that mimic the binding mode of the α-helical HD2 domain of B-Cell Lymphoma 9 (BCL9). As disclosed herein, sulfono-γ-AApeptides can structurally and functionally mimic the α-helical domain of BCL9, and selectively disrupt β-catenin / BCL9 PPIs with even higher potency. More intriguingly, these sulfono-γ-AApeptides can enter cancer cells, bind with β-catenin and disrupt β-catenin / BCL PPI, and exhibit excellent cellular activity, which is much more potent than the BCL9 peptide. Furthermore, enzymatic stability studies demonstrated the remarkable stability of the helical sulfono-γ-AApeptides, with no degradation in the presence of pronase for 24 h, augmenting their biological potential.

The invention relates to the field of oncology, in particular to application of a cancer immunotherapy target and a diagnosis and prognosis prediction biomarker. Wherein at least one marker in the EGFR / Wnt / beta-catenin-LINC00973-miRNA-CD55 / CD59 pathway can be used for evaluating the sensitivity or the prognosis of the cancer immunotherapy.

The present invention provides a method for administering a β-catenin peptide antagonist, and a method for treating solid tumors by administering a β-catenin peptide antagonist.